Investment Rating - The report maintains a "Buy" rating for Tongguan Gold (0340.HK) with a current price of HKD 3.49 [4]. Core Insights - The company is expected to experience significant growth in revenue and profit driven by rising gold prices and strategic acquisitions [10][42]. - The company has successfully expanded its resource base and operational efficiency through multiple acquisitions, including the purchase of mining companies in the Tongguan and Gansu regions [10][15]. - The company’s gold production is projected to increase significantly, with expectations of reaching 3.8 to 4.4 tons by 2027 [38]. Summary by Sections 1. Business Expansion - In the first half of 2025, the company achieved a revenue of HKD 938 million, reflecting a year-on-year growth rate of 21%. The net profit attributable to shareholders reached HKD 312 million, a remarkable increase of 272.6% compared to the previous year [13][14]. - The company has undertaken several initiatives to drive business expansion, including acquiring mining companies and forming strategic partnerships to enhance operational efficiency and reduce costs [15][10]. 2. Resource Growth Potential - The company's total gold resource has increased to 81 tons, with an average grade of 6.5 g/t. The acquisition of Yixin Mining added 26 tons to the resource base [20][22]. - The company operates two mining sites in Su Bei and Tongguan, with significant potential for further resource expansion through ongoing exploration and development efforts [20][30]. 3. Internal Growth and Production Increase - Gold production is expected to reach 2.52 tons in 2024, representing an 85.27% increase year-on-year. The company anticipates continued growth in production, with estimates of 2.6 to 2.9 tons in 2025 and 3.8 to 4.4 tons by 2027 [38][39]. - The company has a strong internal growth potential, particularly in the Tongguan and Su Bei mining areas, as exploration and production transition efforts progress [38]. 4. Financial Forecast and Investment Recommendations - The company is projected to achieve net profits of HKD 1.017 billion, HKD 1.264 billion, and HKD 1.569 billion for the years 2025, 2026, and 2027, respectively. The expected EPS for the same years is HKD 0.19, HKD 0.24, and HKD 0.30 [3][42]. - The report emphasizes that the company's gold mining business is entering a new development phase, with strong internal dynamics and favorable market conditions expected to drive growth [42].

安踏体育 2020 HK 本文内容由 Ryan Lee (李昊谦) 提供 中信证券财富管理(香港) 产品及投资方案部 本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 CSIWM 个股点评 2026 年 1 月 28 日 中国消费品行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 战略布局 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 1 月 28 日发布的题为《Strategic move》 的报告，安踏体育股价在 1 月 27 日上涨 2%，此前公司宣布以每股 35 欧元的价格（含税总对价 15.05 亿欧元/122.8 亿元人民币）现金收购 Artémis（皮诺家族）持有的彪马（PUMA）SE 29.06%股权，其资金全部来自内部资源。此 次交易符合安踏"单聚焦、多品牌、全球化"战略，鉴于彪马在大中华区销售额占比仅 7%（显著低于同业 17%- 30%水平），未来市场空间拓展潜力巨大。安踏管理层确认交 ...

Investment Rating - The report maintains a "Buy" rating for Tongguan Gold (0340.HK) with a current price of HKD 3.49 [4]. Core Insights - The company is expected to experience significant growth in revenue and profit driven by rising gold prices and strategic acquisitions [10][42]. - The company has successfully expanded its resource base and operational efficiency through multiple acquisitions, including the purchase of mining companies in the Tongguan and Gansu regions [10][15]. - The company’s gold production is projected to increase significantly, with a forecasted production of 2.52 tons in 2024, representing a year-on-year growth of 85.27% [38]. Summary by Sections 1. Business Expansion - In the first half of 2025, the company achieved a revenue of HKD 938 million, reflecting a year-on-year growth rate of 21% [13]. - The net profit attributable to shareholders reached HKD 312 million, a remarkable increase of 272.6% compared to the previous year [13]. - The company has undertaken several initiatives to expand its business, including acquiring mining companies and forming strategic partnerships to enhance operational efficiency [15][18]. 2. Resource Growth and Potential - The company's total gold resource has increased to 81 tons, with an average grade of 6.5 g/t following the acquisition of Yixin Mining [20]. - The company operates two mining sites in Su Bei and Tongguan, with significant potential for further resource expansion due to ongoing exploration activities [20][30]. - The average grade of gold resources in Tongguan County is 7.46 g/t, while in Su Bei County, it is 10.21 g/t, indicating high-quality deposits [20]. 3. Internal Growth and Production Increase - Gold production is expected to rise, with projections of 2.6 to 2.9 tons in 2025 and 3.8 to 4.4 tons by 2027 [38]. - The company has shown a consistent increase in gold production since its transition to gold mining in 2017, with a notable increase in production capacity following the acquisition of North East Mining [38][39]. 4. Financial Forecast and Investment Recommendations - The company is projected to achieve net profits of HKD 1.017 billion, HKD 1.264 billion, and HKD 1.569 billion for the years 2025, 2026, and 2027 respectively, with corresponding EPS of HKD 0.19, HKD 0.24, and HKD 0.30 [3][42]. - The report emphasizes the strong internal growth dynamics and favorable market conditions for gold prices, supporting the recommendation to buy the stock [10][42].

Investment Rating - The report maintains a "Buy" rating for Anta Sports [7] Core Views - Anta Sports announced an agreement to acquire approximately 29.06% of PUMA's shares for €15.06 billion (approximately ¥122.8 billion), becoming PUMA's largest shareholder [1][2] - The acquisition is part of Anta's strategy of "single focus, multi-brand, and globalization," aiming to enhance its global brand matrix and leverage PUMA's strengths in professional sports and fashion [2][4] - The transaction is expected to be completed by December 31, 2026, pending regulatory approvals, and is anticipated to have no impact on Anta's dividend capacity for 2025 [3][4] Summary by Sections Acquisition Details - Anta Sports will pay €35 per share, representing a 63% premium over PUMA's closing price of €21.5 on January 27, 2026 [3] - The acquisition is valued at approximately 0.8 times the expected revenue for FY2027, indicating a reasonable valuation for a global brand [3] Financial Projections - Anta forecasts net profits of ¥130.2 billion, ¥140.1 billion, and ¥155.0 billion for 2025, 2026, and 2027 respectively [5] - The target price for Anta is set at HKD 109.21, based on a target PE of 20x for 2026 [5] Market Potential - PUMA's revenue in China is currently low, accounting for about 7% in the fiscal year 2024, indicating significant growth potential in the Chinese market [4] - Anta plans to utilize its established "brand + retail" business model to enhance PUMA's operations in China, aiming for growth above the industry average [4]

证 券 研 究 报 告 康耐特光学（02276.HK）重大事项点评 强推（维持） 配股募资 14 亿港元，强化 XR 业务布局，彰 显成长雄心 事项： 1）公司拟通过配售代理向不少于 6 名承配人配售 2700 万股，配售价格每股 52.00 港元。若悉数配售，预计筹集资金总额约 14.04 亿港元，净额约 14.00 亿 港元。配售完成后总股本预计由 4.80 亿股增至 5.07 亿股。2）根据 AR 圈报 道，字节跳动旗下的 AI 眼镜预计于"春节前后"的时间节点上市，或通过"限 量赠送"替代公开销售。 评论： [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 2,061 | 2,347 | 2,835 | 3,380 | | 同比增速(%) | 17.1% | 13.9% | 20.8% | 19.2% | | 归母净利润(百万元) | 428 | 564 | 696 | 869 | | 同比增速(%) | 31.0% ...

股票研究 /[Table_Date] 2026.01.28 收购 PUMA 29%股权，全球化布局注入 新动力 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 盛开(分析师) | 021-23154510 | shengkai@gtht.com | S0880525040044 | | 钟启辉(研究助理) | 021-23185686 | zhongqihui@gtht.com | S0880125042254 | 本报告导读： 安踏出资 15 亿欧元收购 PUMA 29%股份，成为最大股东。PUMA 业绩面临短期压 力，当前正处清货节奏。我们认为此次收购是安踏推进"单聚焦、多品牌、全球化" 战略的关键一步。 投资要点： | 财务摘要(百万人民币) | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入 | 70826 | 78410 | 85846 | 95707 | | (+/-)% | 13.6% | 10.7% | 9.5% | ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four Phase III trials in 2026 targeting five major indications. This development is expected to position Pfizer favorably in the competitive landscape of next-generation cancer immunotherapy [1][8]. - The collaboration between Pfizer and the company is anticipated to unlock significant global value for 707/PF'4404, serving as a key catalyst for the company's upward trajectory [1][8]. - The company is also increasing its R&D investments, with multiple pipelines expected to yield clinical data soon, enhancing the potential for external licensing opportunities [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. Projections for FY24A and FY25E are RMB 9,108 million and RMB 17,972 million, respectively, indicating a significant growth trajectory [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, reflecting a decline of 19.1% year-on-year, but is expected to rebound to RMB 2,090 million in FY24A and surge to RMB 9,741 million in FY25E, marking a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY25E is projected at RMB 3.84, with a price-to-earnings (P/E) ratio of 5.6, indicating a strong valuation relative to earnings [2][15]. Market Position and Shareholder Structure - The company's market capitalization stands at HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6%, indicating a concentrated ownership structure [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs (antibody-drug conjugates) as a unique advantage [1][8]. - The company has several promising candidates in its pipeline, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1), which are currently in Phase II trials in China [8][12]. Valuation and Forecast Adjustments - The report adjusts the financial forecasts for FY25E and FY26E, reflecting a slight increase in revenue expectations due to the anticipated success of the 707 program [12][13]. - The DCF valuation analysis estimates a per-share value of HKD 37.43, based on a weighted average cost of capital (WACC) of 10.11% and a perpetual growth rate of 2.0% [13][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four global Phase III trials in 2026 targeting five major indications. The combination of PD-(L)1/VEGF dual antibodies is expected to become a cornerstone of next-generation cancer immunotherapy, positioning Pfizer to leverage its internal pipeline synergy and strong clinical execution capabilities [1][8]. - The company is increasing its R&D investments, with several pipelines expected to yield clinical data soon. The core business fundamentals remain robust, providing a safety margin, and the company is projected to achieve significant revenue growth driven by its innovative pipeline [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. The projected sales revenue for FY25E is RMB 17,972 million, reflecting a substantial increase of 97.3% [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, with a year-on-year decline of 19.1%. However, the forecast for FY25E shows a significant increase to RMB 9,741 million, indicating a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY23A was RMB 0.64, expected to rise to RMB 3.84 in FY25E [2][15]. Market Position and Shareholder Structure - The company's market capitalization is approximately HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6% [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs as a unique advantage. The company plans to conduct multiple Phase III trials for various indications, including NSCLC and mCRC, with a focus on rapid patient recruitment [1][8]. - The ongoing clinical trials for other innovative products, such as 705 (PD-1/HER2) and 706 (PD-1/PD-L1), are also expected to contribute to the company's growth and potential licensing opportunities [8][12].

Investment Rating - The report maintains a rating of "Buy" for the company [1] Core Views - As an industry leader, the company's value is expected to undergo systematic re-evaluation driven by the gradual release of new product performance, the leading product quality of "good houses," and the unlocking of capital cycles through commercial REITs [2] Financial Summary - Total revenue is projected to be RMB 202.524 billion in 2023, with a year-on-year growth of 12.3%. However, it is expected to decline to RMB 185.154 billion in 2024, a decrease of 8.6%, and further decline in the following years [4] - Gross profit is expected to decrease from RMB 41.153 billion in 2023 to RMB 32.765 billion in 2024, with a net profit forecasted to drop from RMB 25.610 billion to RMB 15.636 billion in the same period [4] - The company’s PE ratio is projected to increase from 5.27 in 2023 to 7.78 in 2024, while the PB ratio is expected to decrease from 0.36 to 0.32 [4] Investment Recommendations - The report suggests maintaining a "Buy" rating, with an estimated EPS of RMB 1.18, 1.19, and 1.32 for 2025-2027. The target price is set at HKD 20.3 based on a PB of 0.5X for 2026 [8] - The transition between old and new projects is expected to drive performance recovery, with new investments concentrated in prime locations in first-tier and strong second-tier cities [8] - The company’s "good house" initiative is anticipated to lead industry trends, enhancing product strength and long-term competitive advantages [8] Business Operations - The company has established a multi-format commercial operation system centered on office buildings and shopping centers, with stable cash flow and continuous expansion [8] - The successful listing of the first commercial REITs in 2025 marks a breakthrough in the company's asset management strategy, enhancing capital efficiency and long-term valuation [8] Financial Analysis - The company is expected to maintain a strong financial position with a focus on cost control and stable dividend payouts [13] - The development segment contributes over 90% to profits, with a recovery in gross margins anticipated [13] - The company’s liquidity remains strong, with a stable dividend yield [11]

国信纺服观点： 1、标的概况：PUMA 现管理层正推动品牌复苏，短期产生一次性成本，致力于 2027 年恢复增长； 4、风险提示：关税政策不确定性；品牌形象受损；市场的系统性风险。 5、投资建议：看好集团多品牌全球化运营下，持续好于行业的成长潜力。此次安踏对 PUMA 的收购，是公司全 球化战略的进一步深化，PUMA 在全球运动鞋服市场份额领先，在多个专业运动项目以及欧洲等重点市场具有领 先地位和先进经验与安踏集团品牌矩阵有协同性和互补性；PUMA 虽然短期增长乏力、盈利承压，但现管理层正 推动品牌复苏，致力于 2027 年恢复增长，安踏加入后更有望焕发品牌新增长活力。我们维持盈利预测，预计公 司 2025-2027 年归母净利润分别为 132.1/139.3/155.8 亿元，可比口径的利润增长分别为+10.7%/5.5%/11.9% （2024 年剔除 Amer 上市和配售权益摊薄所得的可比口径利润为 119.3 亿元）。维持 107-112 港元目标价，对应 2026 年 20-21X PE，维持"优于大市"评级。 评论： 标的概况：PUMA 现管理层正推动品牌复苏，短期产生一次性成本，致力于 2027 ...